Perampanel: Indications and Clinical Use
Perampanel is an antiepileptic medication indicated for the adjunctive treatment of focal-onset seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures in patients aged 12 years and older. 1
Mechanism of Action
- Perampanel is a first-in-class non-competitive antagonist of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor on post-synaptic neurons 1
- It represents a novel approach by selectively inhibiting excitatory neurotransmission through glutamate receptors, distinguishing it from traditional antiepileptic drugs 2, 3
- The precise mechanism by which perampanel exerts its antiepileptic effects in humans remains unknown 1
FDA-Approved Indications
Perampanel is approved for two specific seizure types: 1, 2
- Focal-onset seizures (partial-onset seizures) with or without secondary generalization in patients ≥12 years
- Primary generalized tonic-clonic seizures as adjunctive therapy in patients ≥12 years
Clinical Efficacy Profile
- Phase III trials demonstrated significant improvement in seizure control when perampanel (up to 12 mg/day) was added to stable regimens of 1-3 antiepileptic drugs 4
- The 50% responder rate (≥50% seizure reduction) ranges from 40-78.7% depending on the study population and treatment duration 5, 6
- Seizure freedom rates range from 12.9-44.4%, with higher rates observed when perampanel is used as first adjunctive therapy rather than late add-on 7, 8
- Efficacy is maintained long-term, with sustained seizure control demonstrated for up to 4 years in extension studies 4
Dosing Considerations
- The medication has a long half-life of approximately 105 hours, allowing for once-daily administration 1
- Steady state is reached in 2-3 weeks 1
- Optimal dosing typically ranges from 4-12 mg/day, with most patients achieving efficacy at 4-8 mg/day 5
- Lower doses (2-4 mg/day) have shown effectiveness in real-world Asian populations 6
Safety and Tolerability Profile
The most common adverse effects are CNS-related and dose-dependent: 4, 5
- Dizziness (most frequent, particularly during titration at 45.5%) 5
- Somnolence (10.2% during titration) 5
- Fatigue and irritability 4
Critical safety considerations include: 2, 4
- Psychiatric and behavioral adverse events have been documented in both adults and pediatric patients, including those without prior psychiatric history 2
- Treatment-emergent adverse events occur more frequently during the 12-week titration period (60.2%) compared to maintenance (28.4%) 5
- Most adverse effects are mild to moderate in intensity and often self-limited 5
- The drug has abuse potential with documented euphoria in 37-46% at doses of 8-36 mg 1
- Perampanel significantly enhances alcohol's impairing effects on psychomotor performance, driving ability, and increases anger, confusion, and depression 1
Clinical Positioning
Perampanel is particularly suitable for: 9, 8
- Adolescent populations due to its favorable cognitive profile and once-daily formulation 9
- Early-line adjunctive therapy, with better outcomes when used as first add-on compared to late add-on therapy 7, 8
- Patients requiring broad-spectrum antiseizure medication coverage 10
Important Drug Interactions
- Strong CYP3A4 inducers (including some antiepileptic drugs like carbamazepine, phenytoin) may require increased perampanel doses 2
- Otherwise, drug interactions are minimal 2
Contraindications and Precautions
- Avoid in patients with severe hepatic impairment (not studied) 1
- Dose adjustment required in mild to moderate hepatic impairment due to 1.8-3.3 fold increase in free drug exposure 1
- Caution with alcohol use due to additive or supra-additive impairment effects 1
- Monitor for seizure aggravation and behavioral problems, particularly during titration 9